Safety and Efficacy of First-Line Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) and Ipilimumab in Non-Small Cell Lung Cancer (NSCLC) von Antonia, S.J, Gettinger, S, Goldman, J, Chow, L.Q, Juergens, R, Borghaei, H, Brahmer, J.R, Shen, Y, Harbison, C, Chen, A.C, Ready, N.E, Rizvi, N.A

Volltext

7LBA Safety, activity, and response durability assessment of single agent rovalpituzumab tesirine, a delta-like protein 3 (DLL3)-targeted antibody drug conjugate (ADC), in small ce... von Pietanza, M.C, Spigel, D, Bauer, T.M, Ready, N.E, Glisson, B.S, Morgensztern, D, Robert, F, Salgia, R, Kochendorfer, M, Patel, M, Strickland, D.K, Govindan, R, Burris, H.A, Rudin, C.M, Dylla, S

Volltext

513 Safety, activity and biomarkers of atezolizumab (MPDL3280A) with platinum-based chemotherapy (chemo) in non-small cell lung cancer (NSCLC): A Phase Ib study von Giaccone, G, Camidge, D.R, Liu, S.V, Powderly, J, Hodi, F.S, Gettinger, S.N, Heist, R.S, Liu, B, Wallin, J, Funke, R, Waterkamp, D, Ready, N.E

Volltext

3096 First-line monotherapy with nivolumab (NIVO) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy, and biomarker analyses von Gettinger, S.N, Hellmann, M.D, Shepherd, F.A, Antonia, S.J, Brahmer, J, Chow, L.Q, Goldman, J, Juergens, R, Borghaei, H, Ready, N.E, Gerber, D.E, Nathan, F, Shen, Y, Harbison, C.T, Rizvi, N

Volltext

3097 Safety and efficacy of first-line nivolumab (NIVO) and ipilimumab (IPI) in non-small cell lung cancer (NSCLC) von Hellmann, M.D, Rizvi, N, Gettinger, S.N, Goldman, J, Chow, L.Q, Juergens, R, Borghaei, H, Brahmer, J, Shen, Y, Harbison, C.T, Nathan, F, Ready, N.E, Antonia, S.J

Volltext

3010 Phase, randomized trial (CheckMate 057) of nivolumab (NIVO) vs docetaxel (DOC) in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC): Subgroup analyses and pati... von Horn, L, Brahmer, J, Reck, M, Borghaei, H, Spigel, D.R, Steins, M, Ready, N.E, Chow, L.Q, Vokes, E.E, Felip, E, Holgado, E, Barlesi, F, Kohlhäufl, M.J, Burgio, M.A, Fayette, J, Gettinger, S.N, Harbison, C.T, Li, A, Finckenstein, F.G, Paz-Ares, L

Volltext

First-Line Monotherapy With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Advanced Non-Small Cell Lung Cancer (NSCLC): Safety, Efficacy, and Correlation of Outcomes With PD-L1 Sta... von Rizvi, N.A, Shepherd, F.A, Antonia, S.J, Brahmer, J.R, Chow, L.Q, Goldman, J, Juergens, R, Borghaei, H, Ready, N.E, Gerber, D.E, Shen, Y, Harbison, C, Chen, A.C, Gettinger, S

Volltext

EP13.06-03 Real-World Outcomes in Patients with 3rd-Line Extensive Stage Small Cell Lung Cancer von Bar, J., Xu, Q., Karve, S., Jeng, E.E., Alexandroff, S., Ready, N.E.

Volltext

Definitive Radiotherapy for Inoperable Stage IIB Non-Small Cell Lung Cancer: Patterns of Care and Comparative Effectiveness Analyses Using the National Cancer Database von Jacobs, C.D., Gao, J., Wang, X., Ready, N.E., Clarke, J., Tong, B., Kelsey, C.R., Suneja, G., Torok, J.A.

Volltext

A Randomized, Open-Label, Multicenter, Global Phase 2 Study of Durvalumab (D), Tremelimumab (T), or D Plus T, in Patients With PD-L1 Low/Negative Recurrent or Metastatic Head and N... von Siu, L., Even, C., Mesía, R., Daste, A., Krauss, J., Saba, N.F., Nabell, L., Ready, N.E., Garcia, I.Brana, Kotecki, N., Zandberg, D.P., Gilbert, J., Mehanna, H., Jarkowski, A., Melillo, G., Armstrong, J.M., Fayette, J.

Volltext

A single-arm, multicenter, phase II trial of osimertinib in patients with epidermal growth factor receptor exon 18 G719X, exon 20 S768I, or exon 21 L861Q mutations von Villaruz, L.C., Wang, X., Bertino, E.M., Gu, L., Antonia, S.J., Burns, T.F., Clarke, J., Crawford, J., Evans, T.L., Friedland, D.M., Otterson, G.A., Ready, N.E., Wozniak, A.J., Stinchcombe, T.E.

Volltext

Safety and Efficacy of First-Line Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) and Ipilimumab in Non-Small Cell Lung Cancer (NSCLC): Metastatic Non-Small Cell Lung Cancer von Antonia, S.J., Gettinger, S., Goldman, J., Chow, L.Q., Juergens, R., Borghaei, H., Brahmer, J.R., Shen, Y., Harbison, C., Chen, A.C., Ready, N.E., Rizvi, N.A.

Volltext

First-Line Monotherapy With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Advanced Non-Small Cell Lung Cancer (NSCLC): Safety, Efficacy, and Correlation of Outcomes With PD-L1 Sta... von Rizvi, N.A., Shepherd, F.A., Antonia, S.J., Brahmer, J.R., Chow, L.Q., Goldman, J., Juergens, R., Borghaei, H., Ready, N.E., Gerber, D.E., Shen, Y., Harbison, C., Chen, A.C., Gettinger, S.

Volltext

417O Phase 3, randomized trial (CheckMate 057) of nivolumab vs docetaxel in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC): subgroup analyses and patient reporte... von Horn, L., Brahmer, J., Reck, M., Borghaei, H., Spigel, D.R., Steins, M., Ready, N.E., Chow, L.Q., Vokes, E.E., Felip, E., Holgado, E., Barlesi, F., Kohlhäufl, M., Burgio, M.A., Fayette, J., Gettinger, S.N., Harbison, C.T., Li, A., Finckenstein, F.G., Paz-Ares, L.

Volltext

Patient-Reported Outcomes in Huntington Disease: Neuro-QOL and HDQLIFE Physical Function Measures von Carlozzi, N.E., Ready, R.E., Frank, S., Cella, D., Hahn, E.A., Goodnight, S.M., Schilling, S.G., Boileau, N. R., Dayalu, P.

Volltext